Both overexpression and mutations affecting the anti-apoptotic protein BCL2 provide cancer cells with a survival advantage [5, 6], leading the scientific and pharmaceutical communities to invest significant efforts into developing drugs specifically targeting this protein [7–9]. Here, BCL2 is linked to cancer.